ResultsIQ

ResultsIQ › Latest results › Rainbow Childrens Medicare Limited

Rainbow Childrens Medicare Limited Q2 FY27 earnings call summary

NSE: RAINBOW · BSE: 543524

Earnings call of 2 Nov 2026, summarised by AI from the filing.

Pre-Ind AS EBITDA margin of around 25%-26% to be maintained even as the network expands.

Key takeaways

  1. Margin guidance Pre-Ind AS EBITDA margin of around 25%-26% to be maintained even as the network expands.
  2. New CFO Group CFO Sudarshan Patodia joined, completing the corporate managerial bandwidth.
  3. Margin risk New bed additions could compress margins by 0.5% to 1% for a few quarters or a year.

Original filing on BSE

Rainbow Childrens Medicare Limited Q2 FY27 results

As filed: Revenue ₹548 cr (+23% year on year), EBITDA ₹170 cr (+14% year on year), PAT ₹83.9 cr (+10% year on year), EBITDA margin 31.0% (−247 bps).

The Q2 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹470 cr (+33% year on year), EBITDA ₹135 cr (+31% year on year), PAT ₹62.5 cr (+16% year on year), EBITDA margin 28.7% (−53 bps). Score 75 of 100, Above trend. Revenue and EBITDA growth were well above the company's own trend; profit growth was in line with it. EBITDA margin fell 53 bps year on year. Profit fell 20% from last quarter. Share price after the results: −5.1% in 29 days (Nifty 500: +0.7%).
  • Q4 FY26: Revenue ₹460 cr (+24% year on year), EBITDA ₹145 cr (+27% year on year), PAT ₹78.2 cr (+37% year on year), EBITDA margin 31.5% (+65 bps). Score 82 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 65 bps year on year. Tax rate 10%. Profit rose ₹21.2 cr on a year ago, more than the ₹6.0 cr it added the year before. Share price after the results: +6.8% in 30 days (Nifty 500: +2.7%).
  • Q3 FY26: Revenue ₹445 cr (+12% year on year), EBITDA ₹147 cr (+10% year on year), PAT ₹73.9 cr (+7% year on year), EBITDA margin 33.0% (−67 bps). Score 47 of 100, In line with trend. Revenue, EBITDA and profit growth were in line with the company's own trend. EBITDA margin fell 67 bps year on year. Share price after the results: +0.1% in 30 days (Nifty 500: +0.4%).
  • Q2 FY26: Revenue ₹445 cr (+7% year on year), EBITDA ₹149 cr (+1% year on year), PAT ₹76.0 cr (−4% year on year), EBITDA margin 33.5% (−177 bps). Score 24 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 177 bps year on year. Share price after the results: +2.1% in 29 days (Nifty 500: −0.4%).
  • Q1 FY26: Revenue ₹353 cr (+7% year on year), EBITDA ₹103 cr (+11% year on year), PAT ₹54.0 cr (+35% year on year), EBITDA margin 29.2% (+100 bps). Score 49 of 100, In line with trend. Revenue growth was well below the company's own trend; EBITDA growth was in line with it; profit growth was well above it. EBITDA margin rose 100 bps year on year. Other income 28% of PBT. Revenue fell 5% from last quarter. Revenue rose ₹23.0 cr on a year ago, against ₹43.0 cr the year before. Share price after the results: −2.0% in 30 days (Nifty 500: +0.2%).
  • Q4 FY25: Revenue ₹370 cr (+9% year on year), EBITDA ₹114 cr (+9% year on year), PAT ₹57.0 cr (+12% year on year), EBITDA margin 30.8% (+2 bps). Score 44 of 100, In line with trend. Revenue and EBITDA growth were below the company's own trend; profit growth was above it. EBITDA margin was flat year on year. Revenue fell 7% from last quarter. Share price after the results: +8.7% in 30 days (Nifty 500: +1.0%).
  • Q3 FY25: Revenue ₹398 cr (+18% year on year), EBITDA ₹134 cr (+14% year on year), PAT ₹69.0 cr (+10% year on year), EBITDA margin 33.7% (−145 bps). Score 59 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA and profit growth were in line with it. EBITDA margin fell 145 bps year on year. Revenue fell 5% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

Rainbow Childrens Medicare Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.